Feb 17, 2019 - Activist hedge fund Starboard Value has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb (NYSE:BMY) shareholders for its $74B deal to buy Celgene (NASDAQ:CELG), Reuters
Feb 14, 2019 - Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
Feb 14, 2019 - Let us take a look at five favorable stocks, poised to beat estimates this earnings season.
Feb 14, 2019 - BMY vs. AZN: Which Stock Is the Better Value Option?
Feb 14, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
Feb 13, 2019 - Exelixis's (EXEL) earnings and revenues beat expectations in the fourth quarter on strong sales of Cabometyx.
Feb 12, 2019 - Bristol-Myers' (BMY) oncology drug, Sprycel in combination with chemotherapy gets EC approval to treat pediatric patients with newly diagnosed Ph+ ALL.
Feb 12, 2019 - Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.
Feb 12, 2019 - Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.
Feb 12, 2019 - AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.